Hikari Power Ltd boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 42,700 shares of the medical research company’s stock after purchasing an additional 1,200 shares during the period. Amgen accounts for 1.0% of Hikari Power Ltd’s investment portfolio, making the stock its 25th biggest holding. Hikari Power Ltd’s holdings in Amgen were worth $7,354,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. TrimTabs Asset Management LLC grew its holdings in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after acquiring an additional 288 shares in the last quarter. American Beacon Advisors Inc. purchased a new position in shares of Amgen during the 1st quarter valued at $106,000. Nelson Roberts Investment Advisors LLC purchased a new position in shares of Amgen during the 1st quarter valued at $121,000. Grove Bank & Trust grew its holdings in shares of Amgen by 87.4% during the 2nd quarter. Grove Bank & Trust now owns 731 shares of the medical research company’s stock valued at $126,000 after acquiring an additional 341 shares in the last quarter. Finally, Enterprise Financial Services Corp grew its holdings in shares of Amgen by 18.0% during the 2nd quarter. Enterprise Financial Services Corp now owns 748 shares of the medical research company’s stock valued at $129,000 after acquiring an additional 114 shares in the last quarter. Hedge funds and other institutional investors own 78.15% of the company’s stock.

Amgen Inc. (AMGN) opened at $170.00 on Monday. Amgen Inc. has a 12-month low of $138.83 and a 12-month high of $191.10. The stock has a market cap of $123,404.80, a P/E ratio of 13.51, a PEG ratio of 2.46 and a beta of 1.37. The company has a debt-to-equity ratio of 1.05, a quick ratio of 5.72 and a current ratio of 6.07.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. During the same period in the prior year, the business posted $3.02 earnings per share. Amgen’s revenue was down .7% compared to the same quarter last year. research analysts anticipate that Amgen Inc. will post 12.66 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be issued a $1.15 dividend. The ex-dividend date of this dividend is Thursday, November 16th. This represents a $4.60 annualized dividend and a yield of 2.71%. Amgen’s dividend payout ratio is currently 41.63%.

Amgen announced that its board has authorized a stock buyback program on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, November 13th. The shares were sold at an average price of $171.58, for a total value of $261,659.50. Following the sale, the executive vice president now directly owns 57,631 shares in the company, valued at $9,888,326.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. Insiders sold 7,050 shares of company stock worth $1,239,673 over the last 90 days. 0.19% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY WARNING: “Hikari Power Ltd Acquires 1,200 Shares of Amgen Inc. (AMGN)” was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/20/hikari-power-ltd-acquires-1200-shares-of-amgen-inc-amgn.html.

AMGN has been the topic of several research analyst reports. BMO Capital Markets restated a “market perform” rating and set a $198.00 price target on shares of Amgen in a report on Thursday, October 26th. Cann reaffirmed a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $203.00 price objective on shares of Amgen in a research note on Thursday, September 7th. Mizuho reaffirmed a “buy” rating and issued a $198.00 price objective (up previously from $183.00) on shares of Amgen in a research note on Thursday, September 28th. Finally, Zacks Investment Research lowered shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 16th. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $190.03.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.